Edwards Lifesciences expands Singapore manufacturing facility

~~SINGAPORE - Edwards Lifesciences Corporation (NYSE: EW), a global leader in the science of heart valves and hemodynamic monitoring, has expanded its heart valve manufacturing facility in Singapore to accommodate growing worldwide demand for tissue heart valves. Edwards has invested some S$95 million in Singapore since 2005.

The Singapore facility contributes to the production of Edwards' surgical and transcatheter tissue heart valves. The company also operates facilities dedicated to the manufacture of heart valves at its global headquarters in Irvine, California, and in Horw, Switzerland. www.edwards.com (ATI).